Evaluation of Annabhedi Sindooram for Managing Anemia Symptoms in Adults: A Clinical Study

A single-arm clinical trial to evaluate the effect of Annabhedi Sindooram in the management of anemia with reference to hemoglobin percentage - nil

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076379

Enrollment

Registered

2024-11-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D50- Iron deficiency anemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with Hb% less than 11 gm/dl. 2. Age group between 18 and 60 years.

Exclusion criteria

Exclusion criteria: 1. Anemia secondary to disorders like liver cirrhosis, rheumatoid arthritis, uremia, or malignancies. 2. Sideroblastic anemia, thalassemia major or minor. 3. Iron deficiency anemia in pregnancy.

Design outcomes

Primary

Measure	Time frame
To evaluate the change in Hb% over the study period at specific time points.Timepoint: Baseline (0th Day): Initial Hb% measurement before the start of treatment. 90th Day: Intermediate Hb% measurement to assess ongoing response. 180th Day (End of Study): Final Hb% measurement to determine the overall effectiveness of the treatment.	—

Secondary

Measure	Time frame
Objective Parameters (CBC, Serum Ferritin, Reticulocyte Count) Subjective Parameters (Fatigue, QoL, Symptom Assessment) Safety Parameters (LFTs, RFTs, AEs):Timepoint: • Objective Parameters (CBC, Serum Ferritin, Reticulocyte Count): o Assessed at Baseline and 180th Day. • Subjective Parameters (Fatigue, QoL, Symptom Assessment): o Evaluated at Baseline 90th Day and 180th Day. • Safety Parameters (LFTs, RFTs, AEs): o Measured at Baseline and 180th Day with continuous monitoring for safety concerns throughout the study duration.	—

Measure

Time frame

Objective Parameters (CBC, Serum Ferritin, Reticulocyte Count) Subjective Parameters (Fatigue, QoL, Symptom Assessment) Safety Parameters (LFTs, RFTs, AEs):Timepoint: • Objective Parameters (CBC, Serum Ferritin, Reticulocyte Count): o Assessed at Baseline and 180th Day. • Subjective Parameters (Fatigue, QoL, Symptom Assessment): o Evaluated at Baseline 90th Day and 180th Day. • Safety Parameters (LFTs, RFTs, AEs): o Measured at Baseline and 180th Day with continuous monitoring for safety concerns throughout the study duration.

—

Countries

India

Contacts

Public ContactDr Aparna Chandran

Pankajakasthuri Ayurveda Medical college and PG centre

jayalekshmi.s94@gmail.com8301050260

Outcome results